Industry news

Popular Tags

industry life COVID-19 FDA science research Hi-Tech medical technology medindustriya business WHO Trump cancer law Alzheimer's disease Industry homeopathy Alzheimer medical brain medicine investment hepatitis c medical and health genome Alzheimer's multiple sclerosis human brain DNA digital biomarkers Nobel Prize medicine and health Parkinson’s disease diabetes hacker attack Amazon startup biology 3D printing biotechnology charity tecnolgy coronavirus cyber-security vaccine health

October 19, 2015, 15:06

Valeant Slumps as U.S. Prosecutors Issue Subpoenas on Prices

Valeant Pharmaceuticals International Inc. shares dropped after U.S. prosecutors issued subpoenas seeking information on drug-pricing decisions, signaling fresh scrutiny just as beleaguered biotechnology investors saw signs that the cost debate may fade away. The drugmaker recently received a subpoena from the U.S. Attorney’s Office in Massachusetts and another from the Manhattan U.S. Attorney’s Office seeking information on its patient assistance programs, drug distribution and pricing decisions, Laval, Quebec-based Valeant said in a statement on Wednesday night. Valeant shares fell 4.7 percent to $168.87 at the New York close.

investment

Site Map